ROCKVILLE, Md. & EDMONTON, Alberta - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) will present five posters with new data on its lupus nephritis medication LUPKYNIS (voclosporin) at two upcoming medical ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...
Title: Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the ENLIGHT-LN Registry Presenting Author: Mohammad Kamgar, M ...
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new ...
If you have been watching Aurinia Pharmaceuticals lately, you are not alone. With the stock closing at $11.27 and boasting a hair-raising 59.2% gain over the past year, it is no wonder investors are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback